Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1112

1.

The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis.

Penner IK, Hartung HP.

Brain. 2019 Sep 1;142(9):2552-2555. doi: 10.1093/brain/awz234. No abstract available.

PMID:
31497861
2.

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators.

Lancet. 2019 Sep 5. pii: S0140-6736(19)31817-3. doi: 10.1016/S0140-6736(19)31817-3. [Epub ahead of print]

PMID:
31495497
3.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators.

Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30238-8. doi: 10.1016/S1474-4422(19)30238-8. [Epub ahead of print]

PMID:
31492652
4.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators.

Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30239-X. doi: 10.1016/S1474-4422(19)30239-X. [Epub ahead of print]

PMID:
31492651
5.

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.

Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL.

Neurology. 2019 Sep 4. pii: 10.1212/WNL.0000000000008189. doi: 10.1212/WNL.0000000000008189. [Epub ahead of print]

PMID:
31484710
6.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5). pii: e590. doi: 10.1212/NXI.0000000000000590. Print 2019 Sep.

7.

Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH Study.

Hartung HP, Mallick R, Bril V, Lewis RA, Sobue G, Lawo JP, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, van Schaik IN; PATH study group.

Eur J Neurol. 2019 Aug 10. doi: 10.1111/ene.14056. [Epub ahead of print]

PMID:
31400231
8.

Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.

Sinnecker T, Hadisurya J, Schneider-Hohendorf T, Schwab N, Wrede K, Gembruch O, Gold R, Hellwig K, Pilgram-Pastor S, Adams O, Albrecht P, Hartung HP, Aktas O, Kraemer M.

BMC Neurol. 2019 Aug 9;19(1):190. doi: 10.1186/s12883-019-1407-2.

9.

Big data in MS-What can we learn from large international observational studies such as MSBase?

Warnke C, Hartung HP.

Mult Scler. 2019 Aug 9:1352458519868982. doi: 10.1177/1352458519868982. [Epub ahead of print] No abstract available.

PMID:
31397200
10.

The Molecular Basis for Remyelination Failure in Multiple Sclerosis.

Gruchot J, Weyers V, Göttle P, Förster M, Hartung HP, Küry P, Kremer D.

Cells. 2019 Aug 3;8(8). pii: E825. doi: 10.3390/cells8080825. Review.

11.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5):e590. doi: 10.1212/NXI.0000000000000590. eCollection 2019 Sep.

12.

No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease.

Lee JI, Gemerzki L, Boerker L, Guthoff R, Aktas O, Gliem M, Jander S, Hartung HP, Albrecht P.

Front Neurol. 2019 Jul 10;10:741. doi: 10.3389/fneur.2019.00741. eCollection 2019.

13.

Drug Treatment of Clinically Isolated Syndrome.

Förster M, Graf J, Mares J, Aktas O, Hartung HP, Kremer D.

CNS Drugs. 2019 Jul;33(7):659-676. doi: 10.1007/s40263-019-00647-x. Review.

PMID:
31290079
14.

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators.

Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5.

PMID:
31285147
15.

Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases.

Graf J, Ingwersen J, Lepka K, Albrecht P, Hartung HP, Ringelstein M, Aktas O.

Acta Neurol Scand. 2019 Oct;140(4):290-295. doi: 10.1111/ane.13144. Epub 2019 Jul 23.

PMID:
31269227
16.

pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis.

Kremer D, Gruchot J, Weyers V, Oldemeier L, Göttle P, Healy L, Ho Jang J, Kang T Xu Y, Volsko C, Dutta R, Trapp BD, Perron H, Hartung HP, Küry P.

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15216-15225. doi: 10.1073/pnas.1901283116. Epub 2019 Jun 18.

PMID:
31213545
17.

Clinical trials in multiple sclerosis: potential future trial designs.

Manouchehri N, Zhang Y, Salter A, Hussain RZ, Hartung HP, Hemmer B, Linker R, Segal BM, Cutter G, Stüve O.

Ther Adv Neurol Disord. 2019 May 13;12:1756286419847095. doi: 10.1177/1756286419847095. eCollection 2019. Review.

18.

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.

Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, Markowitz GS, Margolin DH, Rodriguez CE, Baker DP, Coles AJ.

Mult Scler. 2019 Aug;25(9):1273-1288. doi: 10.1177/1352458519841829. Epub 2019 Apr 15.

PMID:
30986126
19.

Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis.

Schweitzer F, Laurent S, Fink GR, Barnett MH, Reddel S, Hartung HP, Warnke C.

Curr Opin Neurol. 2019 Jun;32(3):305-312. doi: 10.1097/WCO.0000000000000701.

PMID:
30985373
20.

Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm.

Cree BAC, Mares J, Hartung HP.

Curr Opin Neurol. 2019 Jun;32(3):365-377. doi: 10.1097/WCO.0000000000000700.

PMID:
30985372
21.

Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change.

Hartung HP, Graf J, Aktas O, Mares J, Barnett MH.

Curr Opin Neurol. 2019 Jun;32(3):327-337. doi: 10.1097/WCO.0000000000000699.

PMID:
30985371
22.

Challenging a concept: Pulsed treatment regimen-No risk of PML?

Warnke C, Hartung HP.

Mult Scler. 2019 Jul;25(8):1076-1078. doi: 10.1177/1352458519843232. Epub 2019 Apr 9. No abstract available.

PMID:
30964427
23.

Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke: A Meta-analysis.

Lin Y, Schulze V, Brockmeyer M, Parco C, Karathanos A, Heinen Y, Gliem M, Hartung HP, Antoch G, Jander S, Turowski B, Perings S, Kelm M, Wolff G.

JAMA Neurol. 2019 Jul 1;76(7):850-854. doi: 10.1001/jamaneurol.2019.0525.

PMID:
30958530
24.

Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells.

Prozorovski T, Ingwersen J, Lukas D, Göttle P, Koop B, Graf J, Schneider R, Franke K, Schumacher S, Britsch S, Hartung HP, Küry P, Berndt C, Aktas O.

Neurosci Lett. 2019 Jun 21;704:116-125. doi: 10.1016/j.neulet.2019.04.007. Epub 2019 Apr 4.

PMID:
30953735
25.

Biexponential R2* Relaxometry for Estimation of Liver Iron Concentration in Children: A Better Fit for High Liver Iron States.

Barrera CA, Khrichenko D, Serai SD, Hartung HD, Biko DM, Otero HJ.

J Magn Reson Imaging. 2019 Apr 5. doi: 10.1002/jmri.26735. [Epub ahead of print]

PMID:
30950562
26.

Prominent T-Cell Responses against the Acetylcholine Receptor ε Subunit in Myasthenia Gravis.

Neuhaus O, Wiesmüller KH, Hartung HP, Wiendl H.

Neurol Res Int. 2019 Mar 3;2019:1969068. doi: 10.1155/2019/1969068. eCollection 2019.

27.

CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography.

Aktas O, Hartung HP.

Ann Neurol. 2019 May;85(5):615-617. doi: 10.1002/ana.25471. Epub 2019 Apr 10. No abstract available.

PMID:
30900764
28.

Protocol optimization for cardiac and liver iron content assessment using MRI: What sequence should I use?

Barrera CA, Otero HJ, Hartung HD, Biko DM, Serai SD.

Clin Imaging. 2019 Jul - Aug;56:52-57. doi: 10.1016/j.clinimag.2019.02.012. Epub 2019 Feb 20.

PMID:
30889418
29.

An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis.

Amedonu E, Brenker C, Barman S, Schreiber JA, Becker S, Peischard S, Strutz-Seebohm N, Strippel C, Dik A, Hartung HP, Budde T, Wiendl H, Strünker T, Wünsch B, Goebels N, Meuth SG, Seebohm G, Melzer N.

Front Neurol. 2019 Mar 1;10:178. doi: 10.3389/fneur.2019.00178. eCollection 2019.

30.

Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients.

Kraemer M, Schwitalla JC, Diesner F, Aktas O, Hartung HP, Berlit P.

J Neurol. 2019 Jun;266(6):1421-1428. doi: 10.1007/s00415-019-09277-1. Epub 2019 Mar 13.

PMID:
30868219
31.

Remyelination in multiple sclerosis: from concept to clinical trials.

Kremer D, Göttle P, Flores-Rivera J, Hartung HP, Küry P.

Curr Opin Neurol. 2019 Jun;32(3):378-384. doi: 10.1097/WCO.0000000000000692.

PMID:
30865009
32.

Misdiagnoses and delay of diagnoses in Moyamoya angiopathy-a large Caucasian case series.

Graf J, Schwitalla JC, Albrecht P, Veltkamp R, Berlit P, Hartung HP, Aktas O, Kraemer M.

J Neurol. 2019 May;266(5):1153-1159. doi: 10.1007/s00415-019-09245-9. Epub 2019 Feb 25.

PMID:
30805794
33.

Coordinated electrical activity in the olfactory bulb gates the oscillatory entrainment of entorhinal networks in neonatal mice.

Gretenkord S, Kostka JK, Hartung H, Watznauer K, Fleck D, Minier-Toribio A, Spehr M, Hanganu-Opatz IL.

PLoS Biol. 2019 Jan 31;17(1):e2006994. doi: 10.1371/journal.pbio.2006994. eCollection 2019 Jan.

34.

Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects.

Dietrich M, Aktas O, Hartung HP, Albrecht P.

Curr Opin Neurol. 2019 Jun;32(3):346-357. doi: 10.1097/WCO.0000000000000675.

PMID:
30694926
35.

Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats.

Dietrich M, Hecker C, Hilla A, Cruz-Herranz A, Hartung HP, Fischer D, Green A, Albrecht P.

J Vis Exp. 2019 Jan 10;(143). doi: 10.3791/58571.

PMID:
30688311
36.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group.

J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15.

37.

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.

Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group.

J Peripher Nerv Syst. 2019 Mar;24(1):72-79. doi: 10.1111/jns.12303. Epub 2019 Mar 1.

38.

Cognitive impairment and autistic-like behaviour in SAPAP4-deficient mice.

Schob C, Morellini F, Ohana O, Bakota L, Hrynchak MV, Brandt R, Brockmann MD, Cichon N, Hartung H, Hanganu-Opatz IL, Kraus V, Scharf S, Herrmans-Borgmeyer I, Schweizer M, Kuhl D, Wöhr M, Vörckel KJ, Calzada-Wack J, Fuchs H, Gailus-Durner V, Hrabě de Angelis M, Garner CC, Kreienkamp HJ, Kindler S.

Transl Psychiatry. 2019 Jan 16;9(1):7. doi: 10.1038/s41398-018-0327-z.

39.

Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study.

Hartung HP, Graf J, Kremer D.

J Neurol. 2019 Jan 4. doi: 10.1007/s00415-018-09169-w. [Epub ahead of print] Review.

PMID:
30610426
40.

Managing Risks with Immune Therapies in Multiple Sclerosis.

Förster M, Küry P, Aktas O, Warnke C, Havla J, Hohlfeld R, Mares J, Hartung HP, Kremer D.

Drug Saf. 2019 May;42(5):633-647. doi: 10.1007/s40264-018-0782-8. Review.

PMID:
30607830
41.

Monoclonal Antibodies for Multiple Sclerosis: An Update.

Graf J, Aktas O, Rejdak K, Hartung HP.

BioDrugs. 2019 Feb;33(1):61-78. doi: 10.1007/s40259-018-0327-9. Review.

PMID:
30604390
42.

Secretome analysis of nerve repair mediating Schwann cells reveals Smad-dependent trophism.

Schira J, Heinen A, Poschmann G, Ziegler B, Hartung HP, Stühler K, Küry P.

FASEB J. 2019 Apr;33(4):4703-4715. doi: 10.1096/fj.201801799R. Epub 2018 Dec 28.

PMID:
30592632
43.

High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, Bigalke H, Aktas O, Hartung HP, Hefter H.

Neurology. 2019 Jan 1;92(1):e48-e54. doi: 10.1212/WNL.0000000000006688. Epub 2018 Nov 21.

PMID:
30464031
44.

Longevity narratives: Darwinism and beyond.

Hartung H.

J Aging Stud. 2018 Dec;47:84-89. doi: 10.1016/j.jaging.2018.03.002. Epub 2018 Mar 15.

PMID:
30447873
45.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium.

J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

PMID:
30447419
46.

Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination.

Göttle P, Förster M, Gruchot J, Kremer D, Hartung HP, Perron H, Küry P.

Glia. 2019 Jan;67(1):160-170. doi: 10.1002/glia.23535. Epub 2018 Nov 14.

PMID:
30430656
47.

Racial differences in neuromyelitis optica spectrum disorder.

Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, Han M, Leite MI, Palace J, Kim HJ.

Neurology. 2018 Nov 27;91(22):e2089-e2099. doi: 10.1212/WNL.0000000000006574. Epub 2018 Oct 26.

PMID:
30366977
48.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

49.

Immune-mediated neuropathies.

Kieseier BC, Mathey EK, Sommer C, Hartung HP.

Nat Rev Dis Primers. 2018 Oct 11;4(1):31. doi: 10.1038/s41572-018-0027-2. Review.

PMID:
30310069
50.

Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.

Graf J, Ringelstein M, Lepka K, Schaller J, Quack H, Hartung HP, Aktas O, Albrecht P.

Mult Scler. 2018 Nov;24(13):1776-1778. doi: 10.1177/1352458518771276. Epub 2018 Oct 11.

PMID:
30307371

Supplemental Content

Loading ...
Support Center